284 related articles for article (PubMed ID: 26810721)
21. MRI pattern in asymptomatic natalizumab-associated PML.
Wattjes MP; Vennegoor A; Steenwijk MD; de Vos M; Killestein J; van Oosten BW; Mostert J; Siepman DA; Moll W; van Golde AE; Frequin ST; Richert ND; Barkhof F
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):793-8. PubMed ID: 25205744
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
23. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
24. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
25. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
26. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
27. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
[TBL] [Abstract][Full Text] [Related]
28. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
[TBL] [Abstract][Full Text] [Related]
29. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
Lieberman LA; Zeng W; Singh C; Wang W; Otipoby KL; Loh C; Plavina T; Gorelik L; Ransohoff RM; Cahir-McFarland E
Neurology; 2016 Jan; 86(4):375-81. PubMed ID: 26718566
[TBL] [Abstract][Full Text] [Related]
30. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
31. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
32. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
Blankenbach K; Schwab N; Hofner B; Adams O; Keller-Stanislawski B; Warnke C
Neurology; 2019 May; 92(19):e2232-e2239. PubMed ID: 30952796
[TBL] [Abstract][Full Text] [Related]
33. Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
Scarpazza C; De Rossi N; Tabiadon G; Turrini MV; Gerevini S; Capra R
Neurol Sci; 2019 Oct; 40(10):2119-2124. PubMed ID: 31175467
[TBL] [Abstract][Full Text] [Related]
34. Treatment of natalizumab-associated PML with filgrastim.
Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
[TBL] [Abstract][Full Text] [Related]
35. CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study.
Häusler D; Akgün K; Stork L; Lassmann H; Ziemssen T; Brück W; Metz I
Brain Pathol; 2021 Nov; 31(6):e12969. PubMed ID: 33955606
[TBL] [Abstract][Full Text] [Related]
36. JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration.
Henry C; Jouan F; De Broucker T
J Neurol Sci; 2015 Jul; 354(1-2):86-90. PubMed ID: 26003226
[TBL] [Abstract][Full Text] [Related]
37. Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Classen G; Classen C; Bernasconi C; Brandt C; Gold R; Chan A; Hoepner R
J Neurovirol; 2019 Feb; 25(1):133-136. PubMed ID: 30414049
[TBL] [Abstract][Full Text] [Related]
38. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
Lauda F; Fangerau T; Javaheripour-Otto K; Pinkhardt E; Kassubek J; Tumani H
J Neurol; 2015; 262(4):1055-7. PubMed ID: 25663412
[No Abstract] [Full Text] [Related]
39. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
Moser T; Zimmermann G; Baumgartner A; Berger T; Bsteh G; Di Pauli F; Enzinger C; Fertl E; Heller T; Koppi S; Rommer PS; Safoschnik G; Seifert-Held T; Stepansky R; Sellner J
J Neurol; 2024 Jan; 271(1):374-385. PubMed ID: 37728757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]